Evolva Holding SA / Key word(s): AGMEGM 04-Feb-2025 / 17:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Shareholder Clearway requests general meeting Reinach, Switzerland, 4 February 2025 — Evolva Holding SA (SIX: EVE) (“Evolva”) received a letter yesterday by its largest shareholder Clearway Capital Partners ICAV, Dublin, Ireland (“Clearway”) in which Clearway requests a general meeting of Evolva shareholders to be held. Clearway, Evolva’s largest shareholder with a latest reported shareholding of 19.325%, requests a meeting of shareholders with the following agenda items and motions (the language in the Clearway letter is reproduced verbatim below): Agenda item 1: Removal of current board members:
Agenda item 2: Election of new board members:
Agenda item 3: Election of the compensation committee:
Clearway alleges that the current plans of the Board of Directors are not in the best interest of shareholders, which is why Clearway intends to pursue an alternative plan to maximize shareholder value. At the last Annual General Meeting (AGM) of 12 April 2024, the Board of Directors obtained a mandate to pursue opportunities in the area of public mergers and acquisitions, in particular reverse takeovers. The Board of Directors will review, discuss and comment on the agenda item requests in due course, at the latest when the invitation to this year’s AGM is published, which is currently planned for the last week of March 2025. The Board of Directors intends to include Clearway’s agenda items on the agenda for the AGM. Contact Evolva Disclaimer Additional features: File: Evolva: Shareholder Clearway requests general meeting End of Inside Information |
KalVista wants to raise $160M; Prime Medicine’s upsized offering; Applied Tx’s PhIII data
Plus, news about Intellia and ReCode: KalVista aims to raise $160M following pivotal readout: Earlier this week, the company said its oral drug for hereditary